The Evolution and Impact of Combination Therapies in Treating Stage III and IV Melanoma

By HEOR Staff Writer

October 2, 2023

A New Era in Melanoma Treatment

The landscape of treating stage III and IV malignant melanoma (MM), one of the most aggressive skin cancers, has drastically transformed over the past decade. The introduction of immune checkpoint inhibitors (ICIs) such as ipilimumab (IPI) and nivolumab (NIVO) has revolutionized melanoma treatment, offering increased overall survival rates compared to traditional chemotherapy.

The Rise of Combination Therapies

The development and approval of combination therapies have further enhanced treatment effectiveness. These therapies, which combine two active ingredients in one drug, aim to simplify administration, increase patient adherence, and consequently lower costs. Using a combination of NIVO and IPI as a treatment option, showed improved effectiveness compared to using IPI as monotherapy.

The long-term potential of using combination therapy remains a big topic of debate in the industry. When using fixed combinations there is a limit to adjust individual dose regimens which could potentially reduce efficacy. The safety of combination drugs is also not yet fully understood, and their long-term effects remain to be controversial.

Evaluating Cost-effectiveness

Combination therapies have been proven to be more effective, but they also come with higher costs. Studies have found that NIVO plus IPI is cost-effective in Japan, Canada, and the United States when compared to NIVO, IPI, and pembrolizumab. In Switzerland, however, the combination therapy does not prove to be cost-effective compared to vemurafenib.

The effectiveness of BRAF and MEK inhibitors combination therapy varies. Generally this combination is associated with superiority in terms of progression-free survival, overall survival, and objective response rate compared to monotherapy. This however, will need to be confirmed in terms of the long-term effectiveness and cost-effectiveness of these therapies.

Reference url

Recent Posts

Paving the Way for Digital Health Technologies: NICE’s Bold New Strategy for the NHS

By HEOR Staff Writer

October 9, 2025

The National Institute for Health and Care Excellence (NICE) is expanding its technology appraisals programme, and starting April 2026, this will include digital health technologies that are placed on an equal legal footing with medicines in the NHS. This initiative forms part of the NHS 10-year ...
Health Misinformation Autism: The Dangers of Politicized Science in Vaccine and Drug Discourse

By João L. Carapinha

October 7, 2025

The BMJ article “Tylenol, vaccines, and autism: the medical mayhem of the MAGA methodologists” argues that political and ideological actors, notably aligned with the MAGA movement, are promoting health misinformation about autism, vaccines, and paracetamol. They amplify preliminary, misinterprete...
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications

By João L. Carapinha

October 6, 2025

The U.S. Food and Drug Administration (FDA) has recently approved lurbinectedin SCLC therapy in combination with atezolizumab, or with atezolizumab and hyaluronidase-qvfc, for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). This regulatory decision reflects ...